Activating transcription factor 2 expression mediates cell proliferation and is associated with poor prognosis in human non-small cell lung carcinoma

You,Zhenyu; Zhou,Yong; Guo,Yuling; Chen,Wenyan; Chen,Shaoqing; Wang,Xiaolang

doi:10.3892/ol.2015.3922

Activating transcription factor 2 expression mediates cell proliferation and is associated with poor prognosis in human non-small cell lung carcinoma

Authors:
- Zhenyu You
- Yong Zhou
- Yuling Guo
- Wenyan Chen
- Shaoqing Chen
- Xiaolang Wang
View Affiliations

Affiliations: Department of Oncology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Pharmacy, Peking University, Beijing 100083, P.R. China
Published online on: November 16, 2015 https://doi.org/10.3892/ol.2015.3922
Pages: 760-766

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activating transcription factor 2 (ATF2) is a member of the cAMP response element binding protein family that heterodimerizes and activates other transcription factors involved in stress and DNA damage responses, growth, differentiation and apoptosis. ATF2 has been investigated as a potential carcinogenic biomarker in certain types of cancer, such as melanoma. However, its function and clinical significance in non‑small cell lung cancer (NSCLC) has not been well studied. Therefore, the present study aimed to analyze the association between ATF2/phosphorylated (p)‑ATF2 expression and NSCLC malignant behavior, and discuss its clinical significance. Reverse transcription‑quantitative polymerase chain reaction and western blotting were used to detect the expression of ATF2 in NSCLC cell lines and fresh NSCLC tissue samples. In addition, immunohistochemistry (IHC) was performed to identify the location and expression of ATF2 and p‑ATF2 (threonine 71) in paraffin‑embedded sections of NSCLC and adjacent normal tissue. The results demonstrated that ATF2 was markedly overexpressed in the NSCLC cells and significantly overexpressed in the fresh NSCLC tissues compared with the control cells and samples (86 paraffin-embedded tissue sections), respectively (P<0.01). Further data demonstrated that ATF2 expression levels were significantly increased in tumor tissues compared to normal tissues and ATF2 was located in the cytoplasm and nucleus. ATF2 expression was closely associated with adverse clinical characteristics such as TNM stage (P=0.002), tumor size (P=0.018) and metastasis (P=0.027). In addition, nuclear p‑ATF2 staining was positive in 65/86 samples of NSCLC. Furthermore, the Kaplan‑Meier analysis indicated that patients with high levels of ATF2 and p‑ATF2 expression had a significantly shorter overall survival compared with patients exhibiting a low expression (P<0.01 and P<0.05, respectively). Subsequent in vitro experiments revealed that cell growth decreased following knockdown of ATF2 expression using RNA interference, indicating that ATF2 may suppress cell proliferation. Taken together, the results of the present study demonstrated that ATF2 and p‑ATF2 were significantly overexpressed in NSCLC tissues, and ATF2 and p‑ATF2 overexpression predicted significantly worse outcomes for patients with NSCLC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	D'Addario G and Felip E: ESMO guidelines working group: Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 4(Suppl 20): S68–S70. 2009.
3	McElnay P and Lim E: Adjuvant or neoadjuvant chemotherapy for NSCLC. J Thorac Dis. 6(Suppl 2): S224–S227. 2014.PubMed/NCBI
4	Ellis PM, Coakley N, Feld R, Kuruvilla S and Ung YC: Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: A systematic review. Curr Oncol. 22:e183–e215. 2015. View Article : Google Scholar : PubMed/NCBI
5	NSCLC Meta-analyses collaborative group. Arriagada R, Auperin A, et al: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data. Lancet. 375:1267–1277. 2010. View Article : Google Scholar : PubMed/NCBI
6	Spiro SG, Tanner NT, Silvestri GA, et al: Lung cancer: Progress in diagnosis, staging and therapy. Respirology. 15:44–50. 2010. View Article : Google Scholar : PubMed/NCBI
7	Lee IT, Lin CC, Cheng SE, Hsiao LD, Hsiao YC and Yang CM: TNF-α induces cytosolic phospholipase A2 expression in human lung epithelial cells via JNK1/2- and p38 MAPK-dependent AP-1 activation. PloS One. 8:e727832013. View Article : Google Scholar : PubMed/NCBI
8	Bengoa-Vergniory N, Gorroño-Etxebarria I, González Salazar I and Kypta RM: A switch from canonical to noncanonical Wnt signaling mediates early differentiation of human neural stem cells. Stem Cells. 32:3196–3208. 2014. View Article : Google Scholar : PubMed/NCBI
9	Lopez-Bergami P, Lau E and Ronai Z: Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer. 10:65–76. 2010. View Article : Google Scholar : PubMed/NCBI
10	Bhoumik A, Lopez-Bergami P and Ronai Z: ATF2 on the double-activating transcription factor and DNA damage response protein. Pigment Cell Res. 20:498–506. 2007. View Article : Google Scholar : PubMed/NCBI
11	Lau E and Ronai ZA: ATF2-at the crossroad of nuclear and cytosolic functions. J Cell Sci. 125:2815–2824. 2012. View Article : Google Scholar : PubMed/NCBI
12	Shah M, Bhoumik A, Goel V, et al: A role for ATF2 in regulating MITF and melanoma development. PLoS Genet. 6:e10012582010. View Article : Google Scholar : PubMed/NCBI
13	Lau E, Kluger H, Varsano T, et al: PKCε promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell. 148:543–555. 2012. View Article : Google Scholar : PubMed/NCBI
14	Varsano T, Lau E, Feng Y, et al: Inhibition of melanoma growth by small molecules that promote the mitochondrial localization of ATF2. Clin Cancer Res. 19:2710–2722. 2013. View Article : Google Scholar : PubMed/NCBI
15	An JJ, Shi KJ, Wei W, et al: The ROS/JNK/ATF2 pathway mediates selenite-induced leukemia NB4 cell cycle arrest and apoptosis in vitro and in vivo. Cell Death Dis. 4:e9732013. View Article : Google Scholar : PubMed/NCBI
16	Laskin WB and Miettinen M: Epithelioid sarcoma: New insights based on an extended immunohistochemical analysis. Arch Pathol Lab Med. 127:1161–1168. 2003.PubMed/NCBI
17	Song H, Ki SH, Kim SG and Moon A: Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells. Cancer Res. 66:10487–10496. 2006. View Article : Google Scholar : PubMed/NCBI
18	Knippen S, Löning T, Müller V, et al: Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas. Anticancer Res. 29:183–189. 2009.PubMed/NCBI
19	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
20	Yamada H and Sano Y: The biotinylation of the rabbit serotonin antibody and its application to immunohistochemical studies using the two-step ABC method. Histochemistry. 83:285–289. 1985. View Article : Google Scholar : PubMed/NCBI
21	Zhao Y, Li Y, Han J, et al: Helicobacter pylori enhances CIP2A expression and cell proliferation via JNK2/ATF2 signaling in human gastric cancer cells. Int J Mol Med. 33:703–710. 2014.PubMed/NCBI
22	Bhoumik A, Huang TG, Ivanov V, et al: An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest. 110:643–650. 2002. View Article : Google Scholar : PubMed/NCBI
23	Maekawa T, Shinagawa T, Sano Y, et al: Reduced levels of ATF-2 predispose mice to mammary tumors. Mol Cell Biol. 27:1730–1744. 2007. View Article : Google Scholar : PubMed/NCBI
24	Berger AJ, Kluger HM, Li N, et al: Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res. 63:8103–8107. 2003.PubMed/NCBI
25	Duffey D, Dolgilevich S, Razzouk S, Li L, Green R and Gorti GK: Activating transcription factor-2 in survival mechanisms in head and neck carcinoma cells. Head Neck. 33:1586–1599. 2011. View Article : Google Scholar : PubMed/NCBI
26	Knippen S, Löning T, Müller V, et al: Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas. Anticancer Res. 29:183–189. 2009.PubMed/NCBI
27	Zhao Y, Li Y, Han J, et al: Helicobacter pylori enhances CIP2A expression and cell proliferation via JNK2/ATF2 signaling in human gastric cancer cells. Int J Mol Med. 33:703–710. 2014.PubMed/NCBI
28	Bhoumik A, Huang TG, Ivanov V, et al: An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest. 110:643–650. 2002. View Article : Google Scholar : PubMed/NCBI
29	Deng X, Liu H, Huang J, et al: Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: Implications for disease progression. Cancer Res. 68:9663–9670. 2008. View Article : Google Scholar : PubMed/NCBI